Leukemia
Argos Therapeutics reports dosing is initiated in phase I/II trial of AGS-005 in leukemia
Published in Cancer Weekly, February 27th, 2007
GS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's cancer cells.
"B-cell chronic lymphocytic leukemia is the most common adult leukemia in the Western hemisphere, yet there is no broadly applicable standard treatment with the promise to cure for this condition. Therefore, it is important to evaluate new treatment modalities...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2007-02-27)
More Articles from Cancer Weekly
- Cancer Therapy
Biologists identify a major player in cell growth - Cancer Therapy
Improved imaging techniques may help identify breast cancer earlier in overweight women - Cancer Gene Therapy
Data on cancer gene therapy described by researchers at Institute Pasteur - Cancer Gene Therapy
Data on cancer gene therapy described by researchers at University of Texas, Department of Cell Biology - Cancer Gene Therapy
Data on cancer gene therapy reported by researchers at Beatson Laboratories - Cancer Gene Therapy
Findings from Tokyo Medical and Dental University broaden understanding of cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
